宫颈病变中心体异常扩增与高危人乳头状瘤病毒感染相关性  

Relationship of abnormal centrosome amplification in cervical lesions with its high-risk human papillomavirus infection

作　　者：何海[1] 徐建平[2] 刘健玲[1] 李莉芳[1] 黄浩[1] 

机构地区：[1]南方医科大学附属南海医院妇产科,广东佛山528200 [2]暨南大学附属第一医院妇产科,广州510630

出　　处：《中华实用诊断与治疗杂志》2015年第3期247-249,共3页Journal of Chinese Practical Diagnosis and Therapy

摘　　要：目的探讨宫颈病变中中心体异常扩增与高危人乳头状瘤病毒(high-risk human papillomavirus,HR-HPV)感染的关系。方法对46例宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)(CIN组)、43例宫颈鳞状细胞癌患者(宫颈鳞癌组)及20例正常宫颈组织者(对照组)进行宫颈脱落细胞的HR-HPV基因型检测,另采用间接免疫荧光染色技术检测中心体。结果对照组、CIN组及宫颈鳞癌组HR-HPV感染阳性率依次增高,分别为5.00%、78.26%、93.02%,组间比较差异均有统计学意义(P<0.05);CIN组与宫颈鳞癌组细胞中心体异常细胞率分别为(1.76±1.74)%、(4.46±2.08)%,2组比较差异有统计学意义(P<0.05);双变量相关分析显示宫颈病变中,中心体异常细胞率和HR-HPV感染呈正相关(r=0.452,P=0.000)。结论宫颈鳞癌发生、发展过程中,中心体异常扩增与HR-HPV感染密切相关;HR-HPV感染可能通过引起中心体的异常扩增诱发宫颈癌变。Objective To explore the relationship of abnormal centrosome amplification with high-risk human papillomavirus（HR-HPV）infection in cervical lesions.Methods HPV-DNA in cervical exfoliated cells was detected in46 cases of cervical intraepithelial neoplasia（CIN）（CIN group）,43 cases of cervical squamous cell carcinoma（cervical carcinoma group）and 20 cases of normal cervical tissue（control group）.And the centrosome was detected by indirect immunofluorescence.Results The positive rates of HR-HPV infection were 5.00%,78.26% and 93.02% in control group,CIN group and cervical carcinoma group,showing significant differences among groups（P〈0.05）.The rate of abnormal centrosome was（1.76±1.74）% in CIN group,significantly different from that in cervical carcinoma group（（4.46±2.08）%）（P〈0.05）.Bivariate correlation analysis showed that the rate of abnormal centrosome was positively correlated with HR-HPV infection in cervical lesions（r=0.452,P=0.000）.Conclusion In the development and progression of cervical squamous cell carcinoma,abnormal centrosome amplification is closely correlated with HR-HPV infections.HR-HPV infection may lead to cervical cancer by inducing centrosome amplification.

关 键 词：子宫颈鳞状细胞癌 宫颈上皮内瘤变 中心体 高危型人乳头瘤病毒 

分 类 号：R737.33[医药卫生—肿瘤]